Trial Profile
Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Apr 2022 Status changed from recruiting to completed.
- 13 May 2021 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.
- 13 May 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2022.